RT Journal Article
SR Electronic
T1 <em>FOXD1</em> Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 261
OP 268
VO 35
IS 1
A1 SOHEI NAKAYAMA
A1 KENZO SOEJIMA
A1 HIROYUKI YASUDA
A1 SATOSHI YODA
A1 RYOSUKE SATOMI
A1 SHINNOSUKE IKEMURA
A1 HIDEKI TERAI
A1 TAKASHI SATO
A1 NORIHIRO YAMAGUCHI
A1 JUNKO HAMAMOTO
A1 DAISUKE ARAI
A1 KOTA ISHIOKA
A1 KEIKO OHGINO
A1 KATSUHIKO NAOKI
A1 TOMOKO BETSUYAKU
YR 2015
UL http://ar.iiarjournals.org/content/35/1/261.abstract
AB Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC). Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival. Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression. Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.